AR029753A1 - Formas cristalinas de un citrato de azobiciclo (2.2.2)oct-3-ilamina cristalino, sus composiciones farmaceuticas, su uso para la preparacion de medicamentos y procedimiento para su preparacion - Google Patents
Formas cristalinas de un citrato de azobiciclo (2.2.2)oct-3-ilamina cristalino, sus composiciones farmaceuticas, su uso para la preparacion de medicamentos y procedimiento para su preparacionInfo
- Publication number
- AR029753A1 AR029753A1 ARP000102664A ARP000102664A AR029753A1 AR 029753 A1 AR029753 A1 AR 029753A1 AR P000102664 A ARP000102664 A AR P000102664A AR P000102664 A ARP000102664 A AR P000102664A AR 029753 A1 AR029753 A1 AR 029753A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- citrate
- crystal
- oct
- procedure
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 abstract 2
- -1 oct-3-yl Chemical group 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- BWKOZPVPARTQIV-UHFFFAOYSA-N azanium;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [NH4+].OC(=O)CC(O)(C(O)=O)CC([O-])=O BWKOZPVPARTQIV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Formas cristalinas de citrato de (2-benzhidril-1-azo-biciclo[2.2.2]oct-3-il)-(5-isopropil-2-metoxibencil)amina de formula (1) en la que la citada forma cristalina se selecciona entre el grupo consistente en (a) una forma de citrato anhidra no higroscopica que exhibe el patron de difraccion de rayos X en polvo. No. pico 1 2 3 4 5 6 7 8 9 Espacio D (a) 17,61 10,95 8,78 7,96 7,37 6,80 6,57 5,87 5,46 Espacio D (b) 17,74 10,93 9,65 8,25 6,71 5,98 5,67 5,45 4,83 Espacio D (c) 12,3 11,3 6,9 5,9 4,3 4,1 3,5 3,2 b) un citrato monohidrato, forma polimorfica A, que exhibe el patron de difraccion de polvos de rayos X y c) un citrato monohidrato, forma polimorfica B, que exhibe el patron de difraccion de polvo de rayos X de polvo. La composicion farmacéutica que contiene al menos uno de estos polimorfos tiene una estabilidad ventajosa para la formulacion para el tratamiento de émesis aguda en pacientes que reciben quimioterapia. La administracion de esta composicion farmacéutica es convencionalmente oral, mediante preferiblemente comprimidos o cápsulas, e intravenosa. Se describe también un procedimiento para la obtencion de las formas A y B y su uso para la preparacion de medicamentos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13699599P | 1999-06-01 | 1999-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029753A1 true AR029753A1 (es) | 2003-07-16 |
Family
ID=22475353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102664A AR029753A1 (es) | 1999-06-01 | 2000-05-30 | Formas cristalinas de un citrato de azobiciclo (2.2.2)oct-3-ilamina cristalino, sus composiciones farmaceuticas, su uso para la preparacion de medicamentos y procedimiento para su preparacion |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6387925B1 (es) |
| EP (1) | EP1181289A1 (es) |
| JP (1) | JP2003501353A (es) |
| KR (1) | KR20020005055A (es) |
| CN (1) | CN1353712A (es) |
| AP (1) | AP2001002350A0 (es) |
| AR (1) | AR029753A1 (es) |
| AU (1) | AU767331B2 (es) |
| BG (1) | BG106139A (es) |
| BR (1) | BR0011125A (es) |
| CA (1) | CA2372236A1 (es) |
| CO (1) | CO5170468A1 (es) |
| CR (1) | CR6513A (es) |
| CZ (1) | CZ20014270A3 (es) |
| DZ (1) | DZ3051A1 (es) |
| EA (1) | EA004206B1 (es) |
| EE (1) | EE200100655A (es) |
| GT (1) | GT200000086A (es) |
| HK (1) | HK1046407A1 (es) |
| HN (1) | HN2000000076A (es) |
| HR (1) | HRP20010884A2 (es) |
| HU (1) | HUP0201798A3 (es) |
| IL (1) | IL145952A0 (es) |
| IS (1) | IS6129A (es) |
| MX (1) | MXPA01012328A (es) |
| NO (1) | NO20015845L (es) |
| NZ (1) | NZ514762A (es) |
| OA (1) | OA11955A (es) |
| PA (1) | PA8496001A1 (es) |
| PE (1) | PE20010155A1 (es) |
| PL (1) | PL352715A1 (es) |
| SK (1) | SK17342001A3 (es) |
| SV (1) | SV2002000092A (es) |
| TN (1) | TNSN00119A1 (es) |
| TR (1) | TR200103472T2 (es) |
| UY (1) | UY26177A1 (es) |
| WO (1) | WO2000073303A1 (es) |
| ZA (1) | ZA200109839B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006503859A (ja) * | 2002-10-04 | 2006-02-02 | メルク シャープ エンド ドーム リミテッド | 受容体拮抗薬としてのアザ二環式スピロエーテル誘導体 |
| US7414140B2 (en) * | 2003-06-18 | 2008-08-19 | Teva Pharmaceutical Industries Ltd. | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them |
| US7371906B2 (en) | 2004-08-24 | 2008-05-13 | Eastman Kodak Company | Process for photo-oxidative stability improvements |
| US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
| CN110577522B (zh) * | 2018-06-07 | 2022-12-27 | 东莞市东阳光动物保健药品有限公司 | 马罗匹坦柠檬酸盐新晶型及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
| DE9290063U1 (de) * | 1991-05-31 | 1994-02-24 | Pfizer Inc., New York, N.Y. | Chinuclidin-Derivate |
| AU676489B2 (en) * | 1992-11-12 | 1997-03-13 | Pfizer Inc. | Quinuclidine derivative as substance P antagonist |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US6262067B1 (en) * | 1999-06-22 | 2001-07-17 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions |
-
2000
- 2000-05-12 US US09/887,682 patent/US6387925B1/en not_active Expired - Fee Related
- 2000-05-17 TR TR2001/03472T patent/TR200103472T2/xx unknown
- 2000-05-17 BR BR0011125-2A patent/BR0011125A/pt not_active IP Right Cessation
- 2000-05-17 KR KR1020017015324A patent/KR20020005055A/ko not_active Application Discontinuation
- 2000-05-17 CA CA002372236A patent/CA2372236A1/en not_active Abandoned
- 2000-05-17 NZ NZ514762A patent/NZ514762A/xx unknown
- 2000-05-17 EP EP00925526A patent/EP1181289A1/en not_active Withdrawn
- 2000-05-17 SK SK1734-2001A patent/SK17342001A3/sk unknown
- 2000-05-17 MX MXPA01012328A patent/MXPA01012328A/es not_active Application Discontinuation
- 2000-05-17 HU HU0201798A patent/HUP0201798A3/hu unknown
- 2000-05-17 CN CN00808340A patent/CN1353712A/zh active Pending
- 2000-05-17 AU AU44246/00A patent/AU767331B2/en not_active Ceased
- 2000-05-17 OA OA1200100317A patent/OA11955A/en unknown
- 2000-05-17 JP JP2001500628A patent/JP2003501353A/ja active Pending
- 2000-05-17 EE EEP200100655A patent/EE200100655A/xx unknown
- 2000-05-17 CZ CZ20014270A patent/CZ20014270A3/cs unknown
- 2000-05-17 HN HN2000000076A patent/HN2000000076A/es unknown
- 2000-05-17 AP APAP/P/2001/002350A patent/AP2001002350A0/en unknown
- 2000-05-17 WO PCT/IB2000/000663 patent/WO2000073303A1/en not_active Application Discontinuation
- 2000-05-17 PL PL00352715A patent/PL352715A1/xx not_active Application Discontinuation
- 2000-05-17 EA EA200100982A patent/EA004206B1/ru not_active IP Right Cessation
- 2000-05-17 IL IL14595200A patent/IL145952A0/xx unknown
- 2000-05-19 PA PA20008496001A patent/PA8496001A1/es unknown
- 2000-05-26 CO CO00039192A patent/CO5170468A1/es not_active Application Discontinuation
- 2000-05-29 UY UY26177A patent/UY26177A1/es not_active Application Discontinuation
- 2000-05-30 AR ARP000102664A patent/AR029753A1/es unknown
- 2000-05-30 GT GT200000086A patent/GT200000086A/es unknown
- 2000-05-30 PE PE2000000517A patent/PE20010155A1/es not_active Application Discontinuation
- 2000-05-31 TN TNTNSN00119A patent/TNSN00119A1/fr unknown
- 2000-05-31 SV SV2000000092A patent/SV2002000092A/es unknown
- 2000-05-31 DZ DZ000102A patent/DZ3051A1/xx active
-
2001
- 2001-10-26 IS IS6129A patent/IS6129A/is unknown
- 2001-11-23 BG BG106139A patent/BG106139A/bg unknown
- 2001-11-27 CR CR6513A patent/CR6513A/es not_active Application Discontinuation
- 2001-11-27 HR HR20010884A patent/HRP20010884A2/hr not_active Application Discontinuation
- 2001-11-29 ZA ZA200109839A patent/ZA200109839B/xx unknown
- 2001-11-30 NO NO20015845A patent/NO20015845L/no not_active Application Discontinuation
-
2002
- 2002-10-30 HK HK02107840.5A patent/HK1046407A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR023423A1 (es) | Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| NO20085077L (no) | Nye forbindelser | |
| AR021355A1 (es) | Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento | |
| HUP0400636A2 (hu) | Azetidinszármazékokat tartalmazó gyógyszerkészítmények, új azetidinszármazékok és előállításuk | |
| AR029570A1 (es) | Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| AR035320A1 (es) | Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta | |
| ES2065701T3 (es) | Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas. | |
| AR029571A1 (es) | Nueva forma cristalina beta de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| UY27700A1 (es) | Compuestos oxo - azabiclícos. | |
| ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
| NO304113B1 (no) | Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament | |
| AR035889A1 (es) | Citrato de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9- pentaeno y composiciones farmaceuticas que la contienen y su uso para la elaboracion de medicamentos | |
| AR029347A1 (es) | Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica | |
| AR029753A1 (es) | Formas cristalinas de un citrato de azobiciclo (2.2.2)oct-3-ilamina cristalino, sus composiciones farmaceuticas, su uso para la preparacion de medicamentos y procedimiento para su preparacion | |
| UY26211A1 (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo (2.2.2)oct-3-ilamina y sus composiciones farmaceuticas | |
| AR005102A1 (es) | Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento. | |
| AR003434A1 (es) | Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas. | |
| BRPI0409217A (pt) | derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona | |
| ECSP003508A (es) | Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas | |
| ECSP003510A (es) | Polimorfos de un citrato de azobiciclo (2,2,2) oct - 3 - ilamina cristalino y sus composiciones farmaceuticas | |
| SE9202218D0 (sv) | Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation | |
| AR035512A1 (es) | Derivados bencilfenilos, un procedimiento para su preparacion, uso de los mismos y de uvaria klaineri para manufactura de medicamentos, composiciones farmaceuticas y procedimiento para su preparacion | |
| AR042571A1 (es) | L-arabino disacaridos de antraciclinas, sus procesos de preparacion y composiciones farmaceuticas que los contienen y su uso para la preparacion de composisiones farmaceuticas | |
| GT200000104A (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo 2.2.2 oct - 3 - ilamina y sus composicionesfarmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |